CA-QUANERGY-SYSTEMS
18.7.2019 21:02:06 CEST | Business Wire | Press release
Quanergy Systems, Inc., a leading provider of LiDAR (Light Detection and Ranging) sensors and smart sensing solutions, announced a partnership with Chery Automobile, one of the largest automotive manufacturers in China.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190718005616/en/
On June 20th , 2019, Chery unveiled the logo of its new brand Chery Lion, and announced its strategic plan of working with selected partners to solve technological challenges across the ecosystem. Quanergy signed on to Chery Lion’s Smart Partner Program as the LiDAR partner, to focus efforts on advancing autonomous driving and smart cities in China.
“As the autonomous vehicle industry matures, it is imperative to build an ecosystem that supports a transportation network with reliable solutions.” said Dr. Yong Huang, Vice President, Intelligent Vehicle Business Group of Chery. “We’ll work closely with Quanergy on Chery’s autonomous driving vehicles and smart city installations.”
Quanergy‘s S3 automotive grade solid state LiDARs are based on optical phased arrays (OPA) produced in CMOS silicon. These sensors, being fully solid state with no moving parts on any scale, offer an unparalleled level of quality and reliability. Further, the CMOS silicon node used in wafer fabrication is mature, allowing to rapidly scale manufacturing at high yield and meet performance requirements at the lowest price on the market.
On the way to the realization of an autonomous age, smart city infrastructure plays a crucial role as road paver. Internet of Things (IoT) capability in smart cities connects vehicles with essential digital information, reducing traffic congestion and making roads safer.
QORTEX DTC™ (Detection, Tracking, Classification), Quanergy’s proprietary solution based on LiDAR hardware and artificial intelligence (AI) software, can play a key role in monitoring and regulating the flow of vehicles and people at intersections, and can communicate data to the connected vehicles. When combined with 5G cellular network technology, QORTEX DTC provides the necessary awareness and analytical insight into the city’s various connected components and ensures safe and efficient traffic flow.
“China is at the forefront of mobility innovation, and Chery is making massive strides in bringing not only intelligent vehicles but also intelligent transportation systems to market,” said Dr. Louay Eldada, CEO and co-founder of Quanergy. “Chery has selected Quanergy as its LiDAR partner, and together we will forge the next chapter of autonomy in China.”
Through the partnership with Chery, Quanergy is continuing its commitment to deliver its smart sensing technologies to its partners globally. To learn more about these efforts and how LiDAR can specifically be used to support connected roadways and smart city applications, please visit www.quanergy.com/transportation .
About Quanergy Systems, Inc.
Quanergy Systems, Inc. was founded in 2012 and builds on decades of experience of its team in the areas of optics, photonics, optoelectronics, artificial intelligence software and control systems. Headquartered in Sunnyvale, California, in the heart of Silicon Valley, Quanergy offers smart sensing solutions. It is a leading provider of LiDAR sensors and perception software for real-time capture and processing of 3D spatial data and object detection, identification, classification and tracking. Its sensors are disruptive in price, performance, reliability, size, weight and power. Its solutions are applicable in numerous sectors including transportation, security, industrial automation, 3D mapping, mining, agriculture, drones, robotics, smart spaces and 3D-aware smart devices for improved safety, efficiency and quality of life. For more information, visit www.quanergy.com .
About Chery and Chery Lion.
Chery Automobile Co. Ltd. was founded in 1997 in China with the vision of providing affordable yet robust and reliable passenger and commercial vehicles. Chery is manufactured in 13 plants around the world and its range of vehicles is distributed to over 84 countries. Chery Intelligent Vehicle Business Group (IVG) was established on November 10th , 2017 with the aim to concentrate superior resources within Chery Group and to accelerate the process of Chery intelligent business operations. IVG consists of 5 business units: Autonomous Driving BU, V2X Technologies BU, Digital Operations BU, Intelligent Manufacturing BU and Mobility BU. Wuhu Lion Automotive Technologies Co., Ltd. positioned as the operational entity of Chery Intelligent Vehicle Business Group (IVG), is a subsidiary company of Chery Automobile Co., Ltd. It was renamed in December 2017 from the former company of Wuhu Automotive Technology Research Institute Co., Ltd. which was established in July 2014. The company plans to set up R&D centers in different locations for the sake of attracting professional talents and to build core technical competence. The company has already established R&D centers in North America, Wuhu, Nanjing & Shanghai. For more information, visit www.cheryinternational.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190718005616/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom